Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.

Détails

ID Serval
serval:BIB_BD04315DCC0E
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q.
Périodique
Leukemia
Auteur(s)
Mallo M., Cervera J., Schanz J., Such E., García-Manero G., Luño E., Steidl C., Espinet B., Vallespí T., Germing U., Blum S., Ohyashiki K., Grau J., Pfeilstöcker M., Hernández J.M., Noesslinger T., Giagounidis A., Aul C., Calasanz M.J., Martín M.L., Valent P., Collado R., Haferlach C., Fonatsch C., Lübbert M., Stauder R., Hildebrandt B., Krieger O., Pedro C., Arenillas L., Sanz M.Á., Valencia A., Florensa L., Sanz G.F., Haase D., Solé F.
ISSN
1476-5551 (Electronic)
ISSN-L
0887-6924
Statut éditorial
Publié
Date de publication
2011
Peer-reviewed
Oui
Volume
25
Numéro
1
Pages
110-120
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
This cooperative study assessed prognostic factors for overall survival (OS) and risk of transformation to acute myeloid leukemia (AML) in 541 patients with de novo myelodysplastic syndrome (MDS) and deletion 5q. Additional chromosomal abnormalities were strongly related to different patients' characteristics. In multivariate analysis, the most important predictors of both OS and AML transformation risk were number of chromosomal abnormalities (P<0.001 for both outcomes), platelet count (P<0.001 and P=0.001, respectively) and proportion of bone marrow blasts (P<0.001 and P=0.016, respectively). The number of chromosomal abnormalities defined three risk categories for AML transformation (del(5q), del(5q)+1 and del(5q)+ ≥ 2 abnormalities) and two for OS (one group: del(5q) and del(5q)+1; and del(5q)+ ≥ 2 abnormalities, as the other one); with a median survival time of 58.0 and 6.8 months, respectively. Platelet count (P=0.001) and age (P=0.034) predicted OS in patients with '5q-syndrome'. This study demonstrates the importance of additional chromosomal abnormalities in MDS patients with deletion 5q, challenges the current '5q-syndrome' definition and constitutes a useful reference series to properly analyze the results of clinical trials in these patients.
Mots-clé
Adult, Aged, Aged, 80 and over, Anemia, Macrocytic/genetics, Anemia, Macrocytic/mortality, Chromosome Aberrations, Chromosome Deletion, Chromosomes, Human, Pair 5/genetics, Female, Humans, Karyotyping, Male, Middle Aged, Myelodysplastic Syndromes/genetics, Myelodysplastic Syndromes/mortality, Prognosis, Retrospective Studies
Pubmed
Web of science
Open Access
Oui
Création de la notice
23/02/2012 14:45
Dernière modification de la notice
09/05/2019 0:31
Données d'usage